

In re application of:

RENNER et al.

Appl. No.: 10/050,902

Filed: January 18, 2002

For: Molecular Antigen Array

Confirmation No.: 7792

Art Unit: 1648

Examiner: Mosher, M.

Atty. Docket: 1700.0190004/BJD/SJE

Seventh Supplemental Information Disclosure Statement

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Seventh Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Sixth Supplemental Information Disclosure Statement filed on October 29, 2003, in connection with the above-captioned application. A copy of each document is also provided.

A copy of document AB1 is not provided in accordance with the U.S. Patent and Trademark Office pre-OG notice of July 11, 2003, which states "[t]he Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003." Copies of the remaining documents are provided.

The Examiner is referred to the following related, co-pending patent application:

U.S. Patent Application No. 09/848,616, Pub. No. US 2003/0054010 A1, filed May 4, 2001, inventors Sebbel et al., cited herewith as Document AB1.

In accordance with the recent Federal Circuit decision in *Dayco Prods., Inc. v. Total Containment, Inc.* 329 F.3d 1358 (Fed. Cir. 2003), Applicants submit herewith Office Actions from the related copending U.S. Patent Application No. 09/848,616, as Documents AS133-AR134.

The identification of the listed U.S. Patent Application and the Office Actions is not to be construed as a waiver of secrecy as to this application now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited application, Office Actions and the art cited therein during examination of the present application.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Seventh Supplemental Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection, or Notice of Allowance, or an action that otherwise closes prosecution in the application. Attached is our PTO-2038 Credit Card Payment Form in the amount of \$ 180.00 in payment of the fee under 37 C.F.R. § 1.17(p).

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Brian Del Buono

Attorney for Applicants Registration No. 42,473

Date: July U, Zary

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600

(______

256792_1.DOC

•				16 50				Page 1 of 4	
			70	M S TON E	LAIIT, DUCKEI NO). C IE	APPLICATION NO. 10/050,902		
	F	ORM PTO	-1449	Mr 2,	1700.0190004/BJD/SJE FIRST NAMED INVENTOR				
SEVENTH SUPPLEMENTA PLANTS PATENTAL PROPERTY OF THE PATENTY OF THE PATE					RENNER et al. FILING DATE		ART UNIT		
INFOR	SEVEN MATION	DISCLO	SURE STA	EMTATERNE	January 18, 2002		1648		
				U.S. PAT	ENT DOCUMENTS				
EXAMINER NITIAL		DOCUME NUMBER		DATE	NAME	CLASS	SUB-CLASS	FILING DATE	
NITIAL	AA								
	AB1	2003/00	54010 A1	03/20/2003	Sebbel et al.			05/04/2001	
	AC								
	AD								
	AE								
	AF								
	AG								
	AH								
	Al								
	AJ	ļ						1	
	AN			FOREIGN	PATENT DOCUME	NTS			
EXAMINER			JMENT	DATE	COUNTRY	CLAS	SS SUB-CLASS		
INITIAL		NUME	BER	DATE	COOMIN			Yes No	
	AL							Yes	
	AM							No Yes	
	AIVI							No	
	AN							Yes	
	AO5	EP 0	578 293 A	1 01/12/1994	Europe			No.	
	AP5	wo	99/50432 A1 10/07/1999		WIPO			No	
					hor, Title, Date, Pe	rtinent Pages	lian fibroblastoid	myeloid and	
	AR	131	Artelt, P., et al., "Vectors for efficient expression in mammalian fibroblastoid, myeloid and lymphoid cells via transfection or infection," <i>Gene 68</i> :213-219, Elsevier Science Publishers B.V. (1988)						
	AS	131	Kilby, J.M., et al., "Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry," <i>Nat. Med. 4</i> :1302-1307, Nature America, Inc. (199)					,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
	AT	131	McReynolds, L., et al., "Sequence of chicken ovalbumin mRNA," Nature 273:723-728, Macmillan Magazines, Ltd. (1978)						

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

256783_1.DOC

EXAMINER

SKGF Rev. 12/03/03

DATE CONSIDERED

FORM PTO-1449

FORM PTO-1449

FORM SEVENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENTS.

Page 2 of 4

APPLICATION NO. 10/050,902

INFORMATION DISCLOSURE STATEMENTS.

Page 2 of 4

APPLICATION NO. 10/050,902

APPLICATION NO. 10/050,902

APPLICATION NO. 10/050,902

ART UNIT 1648

U.S. PATENT DOCUMENTS DOCUMENT **EXAMINER** CLASS SUB-CLASS **FILING DATE** NAME DATE NUMBER INITIAL AA AB AC AD ΑE AF AG AH ΑI ĀJ AK FOREIGN PATENT DOCUMENTS EXAMINER TRANSLATION SUB-CLASS CLASS COUNTRY DATE **DOCUMENT** INITIAL NUMBER Yes No AL Yes No AM Yes No AN Yes No AO Yes No AΡ OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Wild, C., et al., "Letter to the Editor: A Synthetic Peptide from HIV-1 gp41 Is a Potent Inhibitor of Virus-Mediated Cell-Cell Fusion," AIDS Res. Hum. Retroviruses 9:1051-1053, Mary Ann Liebert, Inc. (1993) AR <u>132</u> Invitrogen Manual, "Sindbis Expression System Version C," from internet web page http://www.invitrogen.com/manuals.html, Catalog No. K750-01 (1996) AS 132 AT DATE CONSIDERED **EXAMINER EXAMINER**: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to Applicant.

Q.F.	Page 3 of 4
ATTY, DOCKET NO. 700.0190004/BJD/SJE	APPLICATION NO. 10/050,902
FORM PTO-1449 SIRST NAMED INVENTOR	R
SEVENTH SUPPLEMENT L INFORMATION DISCLOSURE STATEMENT January 18, 2002	ART UNIT 1648

	,	DOCUME	NIT	0.3.	PATENT DOCUMENTS					
XAMINER NITIAL		DOCUME NUMBER		DATE	NAME	CLASS	SUB-CLASS	FILING DATE		
111712	AA									
	AB									
	AC		_							
	AD									
	AE									
	AF									
	AG	<u> </u>								
	AH									
	Al									
	AJ									
	Al	V								
	1			FORE	IGN PATENT DOCUME	NTS				
EXAMINER INITIAL		DOCU		DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION Yes		
	AL							No.		
	АМ							No Ye:		
	AN							No.		
	AO							No.		
								Ye N		
	AP	OCUED (Lealing Author Title Date Portingnt Pages etc.)								
	AR	133	International Search Report for International Application No. PCT/IB01/00741 mailed March 5, 2002							
			Office Action for related U.S. Application No. 08/848,616, mailed August 30, 2002							
	AS	133								
	AT	133	Office Action for related U.S. Application No. 08/848,616, mailed February 7, 2003							
		100	DATE CONSIDERED							
EXAMINER						JAI		_		

	Page 4 of 4
A TY. DOCKET NO.	APPLICATION NO. 10/050,902
FORM PTO-1449 NAMED INVENTOR	
SEVENTH SUPPLEMENTAL FILES DATE INFORMATION DISCLOSURE STATEMENT Jackéry 18, 2002	ART UNIT 1648

EXAMINER	1	DOCUMENT	0.3.	PATENT DOCUMENT			EU 010 5 1 T		
NITIAL		NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE		
	AA								
	АВ								
	AC								
	AD								
	AE			- 70	1				
	AF								
	AG								
	AH			-10		1 2 - 2 - 71			
	Al								
	AJ								
		ļ							
	Al			INTERIT POOLINE	NTC				
EXAMINER		DOCUMENT		GN PATENT DOCUME	:N15				
INITIAL		NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION Ye		
	AL						Ne Ye		
	AM						No.		
	AN						N		
	AO						Ye N		
							Ye N		
	OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Office Action for related U.S. Application No. 08/848,616, mailed October 31, 2003								
	AR	134 Office	Action for related	U.S. Application No. 08/8	48,616, mailed Octo	per 31, 2003			
	AS								
	АТ								
EXAMINER		<u> </u>			DATE	CONSIDERED)		
EVANINED	Initial if ra	ference considered	L whether or not cit	ation is in conformance with M	APEP 609. Draw line the	rough citation if n	ot in conformance		